Abstract
Abstract In recent years, therapeutic development using immune checkpoint inhibitors has been made in various cancers, and the efficacy of combination therapy with cytotoxic agents, molecular target drugs (including drugs targeting tumor microenvironment), or immune checkpoint inhibitors targeting other than PD-1/PD-L1 have been investigating to improve clinical outcomes. Aims of this presentation will be to understand the development status of combination therapy with immune checkpoint inhibitors and molecule-targeted drugs for thyroid cancer, and to discuss the future perspectives in thyroid cancer in reference to the drug development status in other cancers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
